NBIX - Neurocrine says candidate for childhood epileptic disorder did not meet main goal

• Neurocrine Biosciences ( NASDAQ: NBIX ) announced that its investigational calcium channel blocker NBI-827104 did not meet the main goal in a Phase 2 trial in patients with the pediatric disorder, epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS).
• The placebo-controlled STEAMBOAT trial was designed to evaluate the once-daily administration of NBI-827104 for up to 13 weeks in pediatric patients with EE-CSWS, a disorder characterized by abnormal sleeping patterns.
• When measured after six weeks of therapy, the trial did not meet the primary endpoint of decline in the ratio of the spike-wave index (SWI) from baseline as compared to the placebo, the company said, adding that the study drug was, however, well tolerated.
• "While we did not meet the primary endpoint for this Phase 2 study, we remain committed to advancing care for patients living with epilepsy, including rare pediatric forms," Chief Medical Officer of Neurocrine ( NBIX ) Eiry W. Roberts remarked.
• "We will continue to analyze the rich data set generated from this study to determine next steps."
• Read: Despite multiple catalysts ahead, Wells Fargo launched its coverage on Neurocrine ( NBIX ) in September with an Equal Rating.

For further details see: